Celgene Corp (CELG.O)

CELG.O on Nasdaq

141.51USD
17 Apr 2014
Price Change (% chg)

$-0.35 (-0.25%)
Prev Close
$141.86
Open
$141.98
Day's High
$144.07
Day's Low
$140.29
Volume
2,974,766
Avg. Vol
3,914,493
52-wk High
$174.66
52-wk Low
$110.53

CELG.O

Chart for CELG.O

About

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in... (more)

Overall

Beta: 1.09
Market Cap (Mil.): $57,455.90
Shares Outstanding (Mil.): 406.02
Dividend: --
Yield (%): --

Financials

  CELG.O Industry Sector
P/E (TTM): 41.97 33.23 33.33
EPS (TTM): 3.37 -- --
ROI: 13.50 19.68 18.94
ROE: 25.70 20.37 19.69
Search Stocks

Mylan sues Celgene for blocking Revlimid, Thalomid generics

- Mylan Inc on Thursday sued Celgene Corp to stop the latter's effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market.

03 Apr 2014

Mylan sues Celgene for blocking Revlimid, Thalomid generics

April 3 - Mylan Inc on Thursday sued Celgene Corp to stop the latter's effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market.

03 Apr 2014

UPDATE 2-U.S. FDA approves Celgene drug for psoriatic arthritis

(Adds treatment price, details on how drug works, updates share price)

21 Mar 2014

FDA approves Celgene drug for psoriatic arthritis

- U.S. health regulators on Friday approved a Celgene Corp drug to treat psoriatic arthritis, a type of arthritis associated with the skin disease psoriasis that causes joint pain, stiffness and swelling.

21 Mar 2014

U.S. FDA approves Celgene drug for psoriatic arthritis

March 21 - U.S. health regulators on Friday approved a Celgene Corp drug to treat psoriatic arthritis, a type of arthritis associated with the skin disease psoriasis that causes joint pain, stiffness and swelling.

21 Mar 2014

UPDATE 3-Celgene raises forecasts on cancer drug sales strength

Jan 13 - U.S. biotech company Celgene Corp raised sales and profit forecasts for 2015 and 2017 on Monday, saying its improved long-term outlook was based on current momentum for its blood cancer medicines.

13 Jan 2014

Celgene raises forecasts on cancer drug sales strength

- U.S. biotech company Celgene Corp raised sales and profit forecasts for 2015 and 2017 on Monday, saying its improved long-term outlook was based on current momentum for its blood cancer medicines.

13 Jan 2014

Celgene raises sales, EPS forecasts for 2015, 2017

Jan 13 - Celgene Corp raised its sales and profit forecasts for 2015 and 2017 on Monday, saying its improved view was based on its current momentum.

13 Jan 2014

OncoMed stock doubles after cancer drug deal with Celgene

- Shares of OncoMed Pharmaceuticals Inc more than doubled on Tuesday after the biotechnology company said Celgene Corp would help it develop and market six of its experimental anti-cancer stem cell drugs.

03 Dec 2013

UPDATE 2-OncoMed stock doubles after cancer drug deal with Celgene

* Celgene stock down 1.4 pct (Adds CEO, analyst comments, details on deal; updates share price)

03 Dec 2013

Competitors

  Price Change
Takeda Pharmaceutical Co Ltd (4502.T) ¥4,547 +1.00
Eisai Co., Ltd (4523.T) ¥3,931 -10.00
Johnson & Johnson (JNJ.N) $98.96 +0.21
Pfizer Inc. (PFE.N) $30.25 +0.16
Novartis AG (NOVN.VX) CHF74.70 +0.35
Merck & Co., Inc. (MRK.N) $56.47 +0.21
Roche Holding Ltd. (ROG.VX) CHF254.90 +0.70
Abbott Laboratories (ABT.N) $38.93 +0.55
Sanofi SA (SASY.PA) €75.48 +0.71
AstraZeneca plc (AZN.L) 3,781.50p +23.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$15.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks